African health sciences · 2024
The effectiveness of COVID-19 Heterologous Vaccination: the experience from a Regional Hospital in Cameroon.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Unji Princewill Kum, Tatang Alex Mambap, Angwafor Samuel, Niba Loveline Lum, Porro Adji Minette Jaqueline, Nforniwe Denis Nsame, Chiabi Andreas
Аннотация
BACKGROUND: With most COVID-19 vaccines requiring at least 2 doses, heterologous vaccination will facilitate vaccination programs where vaccine supplies fluctuate. However, with insufficient data on effects of heterologous vaccination in our setting, people remain reluctant to mix.
OBJECTIVES: We seek to assess the effects of heterologous vaccination on morbidity and mortality.
METHODS: This was a 7 months retrospective study for COVID-19 patients managed by the Bamenda Regional Hospital, Cameroon, running from the 18th August 2021 to 28th February 2022. Logistic regression used to asses relationship between predictors and outcome.
RESULTS: Our 1254 participants had a mean age of 50.1(±19.6) years, we had 24 (1.9%) being fully vaccinated, where 7 (29.2%) took heterologous vaccines. Also, 721 (57.5%) had the moderate/severe form of the disease. Those fully vaccinated had lower odds of having severe disease (p=0.037). However, heterologous vaccination compared to homologous vaccination had no significant difference on morbidity (p=0.729). Among patients who died, none was fully vaccinated.
CONCLUSION: The protective effect of vaccination on morbidity was similar in those with heterologous vaccination as well as those who took.
OBJECTIVES: We seek to assess the effects of heterologous vaccination on morbidity and mortality.
METHODS: This was a 7 months retrospective study for COVID-19 patients managed by the Bamenda Regional Hospital, Cameroon, running from the 18th August 2021 to 28th February 2022. Logistic regression used to asses relationship between predictors and outcome.
RESULTS: Our 1254 participants had a mean age of 50.1(±19.6) years, we had 24 (1.9%) being fully vaccinated, where 7 (29.2%) took heterologous vaccines. Also, 721 (57.5%) had the moderate/severe form of the disease. Those fully vaccinated had lower odds of having severe disease (p=0.037). However, heterologous vaccination compared to homologous vaccination had no significant difference on morbidity (p=0.729). Among patients who died, none was fully vaccinated.
CONCLUSION: The protective effect of vaccination on morbidity was similar in those with heterologous vaccination as well as those who took.